Holy Grail faces class action lawsuits
Analysis based on 31 articles · First reported Jun 05, 2026 · Last updated Jun 11, 2026
The class action lawsuits against Holy Grail>>> are expected to negatively impact its stock price and investor confidence. The significant drop in Holy Grail>>>'s stock price following the trial results has already demonstrated a direct negative market impact.
Multiple law firms, including Bronstein, Gewirtz & Grossman, LLC>>>, Faruqi & Faruqi>>>, Robbins LLP>>>, and Robbins Geller Rudman & Dowd LLP>>>, have filed class action lawsuits against Holy Grail>>>. These lawsuits allege that Holy Grail>>> and its officers made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial, which aimed to show a statistically significant reduction in Stage III-IV cancers. The complaints state that Holy Grail>>>'s optimism was overstated and lacked a reasonable basis, concealing adverse facts that diminished the possibility of success. On February 19, 2026, Holy Grail>>> announced that the primary endpoint was not observed, attributing it to insufficient follow-up time. This news led to a dramatic decline of over 50% in Holy Grail>>>'s stock price. Investors who purchased Holy Grail>>> securities between May 13, 2025, and February 19, 2026, are encouraged to join these lawsuits, with a lead plaintiff deadline of August 4, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard